Capricor Therapeutics (NASDAQ:CAPR) Shares Down 4.8% – Here’s What Happened

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price was down 4.8% on Wednesday . The stock traded as low as $15.04 and last traded at $15.04. Approximately 235,997 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 909,716 shares. The stock had previously closed at $15.80.

Analysts Set New Price Targets

Several brokerages have commented on CAPR. HC Wainwright restated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Cantor Fitzgerald increased their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

The company’s 50-day simple moving average is $14.30 and its two-hundred day simple moving average is $13.57. The firm has a market capitalization of $682.05 million, a P/E ratio of -14.19 and a beta of 4.08.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Oppenheimer & Co. Inc. raised its stake in shares of Capricor Therapeutics by 25.2% in the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock worth $1,040,000 after buying an additional 13,762 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Capricor Therapeutics during the third quarter valued at approximately $161,000. FMR LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter worth $370,000. BNP Paribas Financial Markets raised its position in shares of Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 15,872 shares during the period. Finally, Fred Alger Management LLC purchased a new position in shares of Capricor Therapeutics during the 3rd quarter valued at $399,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.